PLoS ONE (Jan 2021)

Bioinformatics analysis identifies DYNC1I1 as prognosis marker in male patients with liver hepatocellular carcinoma

  • Jian Zhou,
  • Yue Zhu,
  • Songlin Ma,
  • Yi Li,
  • Kun Liu,
  • Sihuan Xu,
  • Xin Li,
  • Li Li,
  • Junfang Hu,
  • Yan Liu

Journal volume & issue
Vol. 16, no. 10

Abstract

Read online

Background Liver hepatocellular carcinoma (LIHC) is one of the most common malignant tumors. However, the etiology and exact molecular mechanism of LIHC are still not fully understood, which makes it urgent for us to further study the molecular events behind. Methods In this study, differences in mRNA expression between LIHC samples and normal adjacent samples were found through analyzing the TCGA database, and key targets were sought. We analyzed 371 LIHC samples and 50 normal adjacent samples according to P 2.5, a total of 1092 genes were identified differentially expressed, including 995 up-regulated genes and 97 down-regulated genes. We predicted the interactions of these differentially expressed mRNAs, and used Cyto-Hubba to locate the hub gene-dynein cytoplasmic 1 intermediate chain 1 (DYNC1I1). Results Survival analysis showed that DYNC1I1 was a prognostic factor for LIHC male patients. Functional enrichment indicated that DYNC1I1 and differentially expressed interacting proteins were involved in the cell cycle. Conclusion In conclusion, this study discovers that DYNC1I1 can be used as a prognostic marker for LIHC male patients.